Global Migraine Drugs Market Insights, Forecast to 2025
Table of Contents
1 Study Coverage
- 1.1 Migraine Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Migraine Drugs Market Size Growth Rate by Product
- 1.4.2 Sumatriptan
- 1.4.3 Zolmitriptan
- 1.4.4 Rizatriptan
- 1.4.5 Other Drug
- 1.5 Market by End User
- 1.5.1 Global Migraine Drugs Market Size Growth Rate by End User
- 1.5.2 Hospitals
- 1.5.3 Clinics
- 1.5.4 Household Use
- 1.5.5 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Migraine Drugs Market Size
- 2.1.1 Global Migraine Drugs Revenue 2014-2025
- 2.1.2 Global Migraine Drugs Sales 2014-2025
- 2.2 Migraine Drugs Growth Rate by Regions
- 2.2.1 Global Migraine Drugs Sales by Regions
- 2.2.2 Global Migraine Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Migraine Drugs Sales by Manufacturers
- 3.1.1 Migraine Drugs Sales by Manufacturers
- 3.1.2 Migraine Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Migraine Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Migraine Drugs Revenue by Manufacturers
- 3.2.1 Migraine Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Migraine Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Migraine Drugs Price by Manufacturers
- 3.4 Migraine Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Migraine Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Migraine Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Migraine Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Migraine Drugs Sales by Product
- 4.2 Global Migraine Drugs Revenue by Product
- 4.3 Migraine Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Migraine Drugs Breakdown Data by End User
6 North America
- 6.1 North America Migraine Drugs by Countries
- 6.1.1 North America Migraine Drugs Sales by Countries
- 6.1.2 North America Migraine Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Migraine Drugs by Product
- 6.3 North America Migraine Drugs by End User
7 Europe
- 7.1 Europe Migraine Drugs by Countries
- 7.1.1 Europe Migraine Drugs Sales by Countries
- 7.1.2 Europe Migraine Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Migraine Drugs by Product
- 7.3 Europe Migraine Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Migraine Drugs by Countries
- 8.1.1 Asia Pacific Migraine Drugs Sales by Countries
- 8.1.2 Asia Pacific Migraine Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Migraine Drugs by Product
- 8.3 Asia Pacific Migraine Drugs by End User
9 Central & South America
- 9.1 Central & South America Migraine Drugs by Countries
- 9.1.1 Central & South America Migraine Drugs Sales by Countries
- 9.1.2 Central & South America Migraine Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Migraine Drugs by Product
- 9.3 Central & South America Migraine Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Migraine Drugs by Countries
- 10.1.1 Middle East and Africa Migraine Drugs Sales by Countries
- 10.1.2 Middle East and Africa Migraine Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Migraine Drugs by Product
- 10.3 Middle East and Africa Migraine Drugs by End User
11 Company Profiles
- 11.1 Allergan
- 11.1.1 Allergan Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Allergan Migraine Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Allergan Migraine Drugs Products Offered
- 11.1.5 Allergan Recent Development
- 11.2 Merck
- 11.2.1 Merck Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Merck Migraine Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Merck Migraine Drugs Products Offered
- 11.2.5 Merck Recent Development
- 11.3 Pfizer
- 11.3.1 Pfizer Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Pfizer Migraine Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Pfizer Migraine Drugs Products Offered
- 11.3.5 Pfizer Recent Development
- 11.4 Teva
- 11.4.1 Teva Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Teva Migraine Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Teva Migraine Drugs Products Offered
- 11.4.5 Teva Recent Development
- 11.5 Pfizer
- 11.5.1 Pfizer Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Pfizer Migraine Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Pfizer Migraine Drugs Products Offered
- 11.5.5 Pfizer Recent Development
- 11.6 Johnson & Johnson
- 11.6.1 Johnson & Johnson Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Johnson & Johnson Migraine Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Johnson & Johnson Migraine Drugs Products Offered
- 11.6.5 Johnson & Johnson Recent Development
- 11.7 Endo International
- 11.7.1 Endo International Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Endo International Migraine Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Endo International Migraine Drugs Products Offered
- 11.7.5 Endo International Recent Development
- 11.8 GlaxoSmithKline
- 11.8.1 GlaxoSmithKline Company Details
- 11.8.2 Company Business Overview
- 11.8.3 GlaxoSmithKline Migraine Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 GlaxoSmithKline Migraine Drugs Products Offered
- 11.8.5 GlaxoSmithKline Recent Development
- 11.9 Impax
- 11.9.1 Impax Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Impax Migraine Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Impax Migraine Drugs Products Offered
- 11.9.5 Impax Recent Development
- 11.10 Abbott
- 11.10.1 Abbott Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Abbott Migraine Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Abbott Migraine Drugs Products Offered
- 11.10.5 Abbott Recent Development
- 11.11 Bayer
- 11.12 Eli Lilly
- 11.13 Ethypharm
- 11.14 Kowa Pharmaceuticals America
- 11.15 Winston Pharmaceuticals
- 11.16 AstraZeneca
12 Future Forecast
- 12.1 Migraine Drugs Market Forecast by Regions
- 12.1.1 Global Migraine Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Migraine Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Migraine Drugs Market Forecast by Product
- 12.2.1 Global Migraine Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Migraine Drugs Revenue Forecast by Product 2019-2025
- 12.3 Migraine Drugs Market Forecast by End User
- 12.4 North America Migraine Drugs Forecast
- 12.5 Europe Migraine Drugs Forecast
- 12.6 Asia Pacific Migraine Drugs Forecast
- 12.7 Central & South America Migraine Drugs Forecast
- 12.8 Middle East and Africa Migraine Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Migraine Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
The global Migraine Drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Migraine Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Migraine Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Migraine Drugs in these regions.
This research report categorizes the global Migraine Drugs market by top players/brands, region, type and end user. This report also studies the global Migraine Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Allergan
Merck
Pfizer
Teva
Pfizer
Johnson & Johnson
Endo International
GlaxoSmithKline
Impax
Abbott
Bayer
Eli Lilly
Ethypharm
Kowa Pharmaceuticals America
Winston Pharmaceuticals
AstraZeneca
Market size by Product
Sumatriptan
Zolmitriptan
Rizatriptan
Other Drug
Market size by End User
Hospitals
Clinics
Household Use
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Migraine Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Migraine Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Migraine Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Migraine Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Migraine Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Migraine Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.